Generic semaglutide in Canada and Brazil is poised for significant volume growth, but price competition will determine the value pool
AI summary card
Generic semaglutide in Canada and Brazil is poised for significant volume growth, but price competition will determine the value pool
Goldman Sachs expects generic entry to increase GLP-1 penetration and semaglutide volumes, but severe price erosion will cause the Canadian diabetes market to contract under the base case; Brazil, by contrast, offers stronger volume-growth potential due to low penetration and a large patient base.
- In Canada's type 2 diabetes market, GLP-1 penetration is expected to rise from 18% in FY2025 to 40% in FY2029, while semaglutide volume increases from approximately 11 million units to approximately 29 million units.
- The Canadian base case assumes 65% to 80% price erosion from generics, reducing the semaglutide market opportunity from approximately US$1.2 billion in FY2025 to approximately US$550 million in FY2029.
- Brazil's total semaglutide sales opportunity is expected to rise from BRL5.676 billion in FY2025 to BRL10.743 billion in 2029, with volume increasing from approximately 6 million units to 25.6 million units.
- Median sensitivity scenarios in both Canada and Brazil imply approximately 0% to 1% potential upside to Sandoz's generic-business valuation forecasts, although the company has not yet incorporated the opportunity into its forecasts.
- Novo Nordisk is expected to maintain a high market share in the near term through pricing close to generics, authorized generic brands, supply across all dosage forms, and brand and channel advantages.
Report interpretation
Overview
The report assesses the generic-drug opportunity in Canada and Brazil after semaglutide loses exclusivity in certain international markets starting in 2026. It covers type 2 diabetes and obesity indications and analyzes volume, pricing, and share sensitivities for Novo Nordisk and Sandoz. The authors believe both markets offer clear potential for volume expansion, but will face intense competition and consumer-goods-like dynamics from the outset, with price declines serving as the key determinant of the value pool.
Core views
Low-cost generics in Canada's type 2 diabetes market will move GLP-1s earlier in the treatment pathway and broaden coverage, but under the base case, prices decline faster than volumes grow, leading to a contraction in market value. The Canadian obesity generic opportunity remains conservative, constrained by uncertainty around indication labels, dosage-form breadth, pricing, and out-of-pocket demand. Brazil has lower penetration, a larger addressable population, and a predominantly out-of-pocket market, thereby offering more substantial long-term volume-growth potential. Novo Nordisk is expected to defend a meaningful share through authorized generic products, dosage-form coverage, supply capabilities, and brand relationships, while Sandoz may gain a competitive share through its multi-partner strategy and local channel capabilities.
Analysis framework
The analysis uses a bottom-up market model and base, downside, and upside sensitivity scenarios to project 2026-2029 volumes and sales based on target populations, GLP-1 penetration, semaglutide's share within GLP-1, unit-price erosion, retail rebates, and manufacturer market shares.
Methodology notes
Constructs market size based on population, penetration, unit volumes, and pricing
Separately estimates GLP-1 adoption, semaglutide share, treatment-unit volumes, and net prices for type 2 diabetes and obesity populations to estimate potential sales of branded and generic drugs.
Tests the impact of changes in penetration, price erosion, and share on outcomes
Generates sales ranges for Novo Nordisk and Sandoz by adjusting GLP-1 penetration, generic price discounts, cash-pay demand, reimbursement expansion, and competitive shares.
Assesses how the number of competitors, dosage forms, supply, and channels affect share
Incorporates approved and pending generic products, Novo Nordisk authorized generic brands, manufacturing routes, supply scale, and prescriber/patient willingness to switch.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Novo Nordisk (NOVOb.CO, NVO)Supplier of originator semaglutide products and authorized generic brands
- Strengths
- Brand and prescriber relationships, coverage across all dosage forms, device capabilities, recombinant-fermentation supply capacity, and price defense through Plosbrio and Povitzra.
- Weaknesses
- Faces generic-drug price competition after patent expiry, placing pressure on market share and realized prices.
- Comparison
- Near-term share is expected to remain materially higher than that of any individual generic-drug manufacturer, but may decline meaningfully in both Canada and Brazil by 2029.
- Risks
- Faster generic approvals, accelerated price declines, patient switching to generics, and competition from drugs with new mechanisms.
- Sandoz Group AG (SDZ.S)Potential beneficiary of generic semaglutide
- Strengths
- Strong Canadian market position, with a multi-partner strategy that improves supply flexibility; its Brazilian product Owozy was approved in July 2026 and is partnered with Adalvo.
- Weaknesses
- May enter the Canadian market relatively late, the commercialization opportunity is not yet included in company forecasts, and it is sensitive to pricing, supply, and regulatory timing.
- Comparison
- Expected to obtain a smaller but competitive market share, materially below Novo Nordisk's near-term share.
- Risks
- Regulatory approval delays, active pharmaceutical ingredient or supply-quality issues, continued competitor entry, and a greater-than-expected price war.
- Hypera Pharma (HYPE3.SA)Relevant Brazilian local pharmaceutical-market exposure
- Strengths
- Potential spillover benefit from Brazilian GLP-1 market expansion and improvements in the local distribution environment.
- Weaknesses
- The report provides no semaglutide commercialization share or specific forecast for the company.
- Comparison
- The report offers limited quantification of its direct impact.
- Risks
- Brazilian generic-drug competition, pricing pressure, and changes in market access.
Key data
- Canada Type 2 Diabetes GLP-1 PenetrationApproximately 18% in FY2025; approximately 40% in the FY2029 base caseLower-cost generics are expected to drive broader adoption.
- Canada Type 2 Diabetes Semaglutide VolumeApproximately 11 million units (FY2025) to approximately 29 million units (FY2029)Nearly threefold growth under the base case.
- Canada Type 2 Diabetes Market SizeApproximately US$1.2 billion (FY2025) to approximately US$550 million (FY2029)Price erosion offsets volume growth under the base case; 2029 market size in downside and upside scenarios is approximately US$175 million and US$1.5 billion, respectively.
- Canada Price-Erosion AssumptionApproximately 65% in 2026, followed by an additional approximately 5% decline annuallyBased on Canada's tiered generic-drug pricing framework and sustained competition.
- Canada Novo Nordisk ShareType 2 diabetes volume share of approximately 60% to 80% in 2026; approximately 30% to 50% in 2029Supported by authorized generic products, price matching, and supply across all dosage forms.
- Canada Sandoz ShareApproximately 5% to 15% in type 2 diabetes in 2027; approximately 10% to 20% in 2029Corresponds to annual sales opportunities in the mid-to-high double-digit millions from 2027 to 2029.
- Brazil Semaglutide Sales OpportunityBRL5.676 billion (FY2025) to BRL10.743 billion (2029)Includes Ozempic, Wegovy, Rybelsus, and generics.
- Brazil Semaglutide VolumeApproximately 6 million units (FY2025) to approximately 25.6 million units (2029)Low penetration and a larger addressable population support approximately fourfold growth.
- Brazil Sandoz ShareApproximately 2% to 6% in 2027; approximately 6% to 10% in 2029The median scenario corresponds to an annual sales opportunity of approximately US$50 million to US$125 million from 2027 to 2029.
Impact & implications
For the industry, the key question for generic semaglutide is not whether demand will grow, but whether new patients, reimbursement expansion, and cash-pay channels can grow faster than prices decline. For Sandoz, Canada and Brazil are early markets to validate its multi-partner, supply, and local commercialization capabilities; the valuation impact is currently limited but offers upside optionality. For Novo Nordisk, the risk of share loss is real, but its authorized-generic strategy, brand loyalty, device capabilities, and supply advantages may cushion the near-term impact; revenue pressure will depend more on the extent of pricing defense.
Risks
- The magnitude and pace of generic-drug price erosion may be higher or lower than base-case assumptions.
- There is substantial uncertainty around approval timing, launch sequencing, and supply capabilities for competing generics.
- Patient and physician preferences for originator brands, devices, and dosage forms may limit switching rates.
- Changes in public and private insurance coverage, cash-pay demand, and off-label obesity use may materially alter volumes.
- Active pharmaceutical ingredient quality, manufacturing scale-up, and supply disruptions may affect generic launches and shares.
- Mounjaro and other new-mechanism or oral medicines may erode semaglutide's share of the GLP-1 market.
- Performance in the early Canadian and Brazilian markets may not be directly extrapolable to future global genericization.
What to watch
- Approval and year-end launch progress for Sandoz's Canadian type 2 diabetes product.
- Sandoz's update on its semaglutide commercialization strategy and forecasts at its September 8, 2026 Capital Markets Day.
- New generic approvals in Canada, launch timing and pricing for Novo Nordisk's Plosbrio and Povitzra.
- Actual Canadian GLP-1 prescription volumes, semaglutide share, and growth in cash-pay channels.
- Supply, distribution, and actual pricing of Owozy and other approved generics in Brazil.
- Novo Nordisk's authorized-generic pricing, market share, and all-dosage-form supply performance in both countries.
- Expansion of public and private reimbursement, obesity-indication coverage, and changes in the compounded-products market.